BR112014008775A2 - camundongo de cadeia pesada de imunoglobulina restrita - Google Patents
camundongo de cadeia pesada de imunoglobulina restritaInfo
- Publication number
- BR112014008775A2 BR112014008775A2 BR112014008775A BR112014008775A BR112014008775A2 BR 112014008775 A2 BR112014008775 A2 BR 112014008775A2 BR 112014008775 A BR112014008775 A BR 112014008775A BR 112014008775 A BR112014008775 A BR 112014008775A BR 112014008775 A2 BR112014008775 A2 BR 112014008775A2
- Authority
- BR
- Brazil
- Prior art keywords
- heavy chain
- immunoglobulin heavy
- human
- mouse
- gene segments
- Prior art date
Links
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 title abstract 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 241000699666 Mus <mouse, genus> Species 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 241000699670 Mus sp. Species 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
resumo patente de invenção: "camundongo de cadeia pesada de imunoglobulina restrita". a presente invenção refere-se a camundongos com um locus da cadeia pesada de imunoglobulina restrita, em que o locus é caracterizado por um único segmento gênico vh humano polimórfico, uma pluralidade de segmentos gênicos dh humanos e uma pluralidade de segmentos gênicos jh. são providos métodos para fazer sequências de anticorpos que se ligam a um antígeno (por exemplo, um antígeno viral), compreendendo a imunização de um camundongo com um antígeno de interesse, em que o camundongo compreende um único segmento gênico vh humano, uma pluralidade de segmentos gênicos dh humanos e uma pluralidade de segmentos gênicos jh, no locus de cadeia pesada de imunoglobulina endógeno.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547974P | 2011-10-17 | 2011-10-17 | |
US201261597969P | 2012-02-13 | 2012-02-13 | |
US201261658459P | 2012-06-12 | 2012-06-12 | |
PCT/US2012/060487 WO2013059230A1 (en) | 2011-10-17 | 2012-10-17 | Restricted immunoglobulin heavy chain mice |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014008775A2 true BR112014008775A2 (pt) | 2017-06-13 |
BR112014008775A8 BR112014008775A8 (pt) | 2017-09-12 |
Family
ID=47144131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014008775A BR112014008775A8 (pt) | 2011-10-17 | 2012-10-17 | Métodos para produzir camundongos com locus restrito de cadeia pesada de imunoglobulina, para obter célula ou tecido de camundongos, para produzir sequência de ácido nucleico que codifica domínio variável de cadeia pesada humano, bem como ácido nucleico |
Country Status (26)
Country | Link |
---|---|
US (5) | US10246509B2 (pt) |
EP (3) | EP4074833A1 (pt) |
JP (6) | JP6271435B2 (pt) |
KR (6) | KR20160098514A (pt) |
CN (3) | CN104024418B (pt) |
AU (4) | AU2012326283C1 (pt) |
BR (1) | BR112014008775A8 (pt) |
CA (1) | CA2850534A1 (pt) |
CY (2) | CY1119335T1 (pt) |
DK (2) | DK3216871T3 (pt) |
ES (2) | ES2906462T3 (pt) |
HR (2) | HRP20220253T1 (pt) |
HU (2) | HUE057680T2 (pt) |
IL (5) | IL292030B2 (pt) |
IN (1) | IN2014CN03572A (pt) |
LT (2) | LT2627773T (pt) |
MX (1) | MX355062B (pt) |
MY (1) | MY172946A (pt) |
PL (2) | PL2627773T3 (pt) |
PT (2) | PT2627773T (pt) |
RS (2) | RS56458B1 (pt) |
RU (2) | RU2743589C2 (pt) |
SG (3) | SG10202010120XA (pt) |
SI (2) | SI2627773T1 (pt) |
WO (1) | WO2013059230A1 (pt) |
ZA (1) | ZA201402455B (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
DK3622813T3 (da) | 2009-07-08 | 2021-05-03 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
NZ707327A (en) | 2010-08-02 | 2017-01-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
DE12192727T1 (de) | 2011-02-25 | 2013-07-11 | Regeneron Pharmaceuticals, Inc. | ADAM6 Mäuse |
PT3572517T (pt) | 2011-08-05 | 2021-06-23 | Regeneron Pharma | Murganhos da cadeia leve universal humanizada |
ES2612935T3 (es) | 2011-09-19 | 2017-05-19 | Kymab Limited | Anticuerpos, dominios variables y cadenas adaptados para su uso en seres humanos |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
PL2627773T3 (pl) | 2011-10-17 | 2017-11-30 | Regeneron Pharmaceuticals, Inc. | Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
SI2793567T1 (sl) | 2011-12-20 | 2019-05-31 | Regeneron Pharmaceuticals, Inc. | Humanizirane lahkoverižne miši |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
ME03551B (me) | 2012-06-12 | 2020-07-20 | Regeneron Pharma | Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca |
WO2014130690A1 (en) * | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
WO2015112790A2 (en) * | 2014-01-24 | 2015-07-30 | Children's Medical Center Corporation | High-throughput mouse model for optimizing antibody affinities |
SG10201808083VA (en) | 2014-03-21 | 2018-10-30 | Regeneron Pharma | Vl antigen binding proteins exhibiting distinct binding characteristics |
CN106255410B (zh) | 2014-03-21 | 2020-01-10 | 瑞泽恩制药公司 | 产生单结构域结合蛋白的非人动物 |
JP7325928B2 (ja) | 2014-05-16 | 2023-08-15 | アブリンクス エン.ヴェー. | 改善された免疫グロブリン可変ドメイン |
CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
KR102482103B1 (ko) | 2016-01-13 | 2022-12-28 | 리제너론 파마슈티칼스 인코포레이티드 | 조작된 중쇄 다양성 영역을 갖는 설치류 |
CN109195443A (zh) | 2016-02-16 | 2019-01-11 | 雷杰纳荣制药公司 | 具有突变型犬尿氨酸酶基因的非人动物 |
RU2745563C2 (ru) | 2016-05-20 | 2021-03-29 | Регенерон Фармасьютикалс, Инк. | Способы преодоления иммунологической толерантности с использованием множества направляющих рнк |
SI3462853T1 (sl) | 2016-06-03 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo |
KR102319069B1 (ko) | 2016-11-04 | 2021-11-01 | 리제너론 파마슈티칼스 인코포레이티드 | 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물 |
CN108265035A (zh) * | 2016-12-30 | 2018-07-10 | 深圳先进技术研究院 | 一种进化噬菌体宿主特异性的方法 |
PT3720279T (pt) | 2017-12-05 | 2022-10-06 | Regeneron Pharma | Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos |
CN112040769B (zh) | 2018-03-24 | 2023-05-16 | 瑞泽恩制药公司 | 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途 |
CA3093850A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
KR102444180B1 (ko) | 2018-06-14 | 2022-09-16 | 리제너론 파마슈티칼스 인코포레이티드 | 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물 |
TW202110323A (zh) | 2019-06-05 | 2021-03-16 | 美商再生元醫藥公司 | 具有表現自κ 基因座的有限λ 輕鏈組庫的非人類動物及其用途 |
WO2021113297A1 (en) | 2019-12-02 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
CA3187680A1 (en) | 2020-09-11 | 2022-03-17 | Yashu Liu | Identification and production of antigen-specific antibodies |
IL303626A (en) | 2020-12-16 | 2023-08-01 | Regeneron Pharma | Mice expressing human FC alpha receptors |
TW202241934A (zh) | 2020-12-23 | 2022-11-01 | 美商再生元醫藥公司 | 編碼錨定修飾抗體之核酸及其用途 |
WO2023179620A1 (en) * | 2022-03-21 | 2023-09-28 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin and mhc loci |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69637481T2 (de) * | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
ATE387495T1 (de) | 1996-12-03 | 2008-03-15 | Amgen Fremont Inc | Vollkommen humane antikörper die egfr binden |
CN1203922A (zh) | 1997-03-21 | 1999-01-06 | 三共株式会社 | 人源化抗人fas抗体 |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
FI105105B (fi) * | 1998-02-27 | 2000-06-15 | Finnish Immunotechnology Ltd O | Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan |
EP1183344A4 (en) | 1999-05-27 | 2003-06-25 | Human Genome Sciences Inc | ADAM POLYNUCLEOTIDES AND POLYPEPTIDES |
CN101498731A (zh) * | 2000-05-18 | 2009-08-05 | 日本烟草产业株式会社 | 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途 |
US20020028488A1 (en) * | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
AU8470301A (en) | 2000-08-03 | 2002-02-18 | Wim-Van Schooten | Production of humanized antibodies in transgenic animals |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
US7034134B2 (en) | 2001-04-26 | 2006-04-25 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
EP1632571B1 (en) | 2001-05-11 | 2012-11-28 | Kyowa Hakko Kirin Co., Ltd. | Human artificial chromosome containing human antibody Lambda light chain and non-human animal containing the human artificial chromosome capable of genetic transmission |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
AU2004242614B2 (en) | 2003-05-30 | 2011-09-22 | Merus N.V. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CA2532117C (en) | 2003-07-15 | 2012-07-10 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
US20050153392A1 (en) | 2003-08-11 | 2005-07-14 | Roland Buelow | Transgenesis with humanized immunoglobulin loci |
EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
RU2251699C1 (ru) | 2003-09-25 | 2005-05-10 | Киселев Всеволод Иванович | Способ ранней и доклинической диагностики цервикального рака |
WO2005038001A2 (en) | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis by sperm-mediated gene transfer |
CN101076542A (zh) * | 2004-09-13 | 2007-11-21 | 伊沃詹尼克斯有限公司 | 特异性针对肝细胞癌和其他癌的抗体及其用途 |
EP1874817A2 (en) | 2005-04-29 | 2008-01-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
EP1991580A2 (en) | 2006-01-25 | 2008-11-19 | Erasmus University Medical Center Rotterdam | Generation of heavy-chain only antibodies in transgenic animals |
AU2007235496B2 (en) | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
WO2009138519A1 (en) * | 2008-05-16 | 2009-11-19 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
EP3255144A1 (en) * | 2007-08-10 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin |
AU2008304574A1 (en) * | 2007-09-24 | 2009-04-02 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
KR20100103810A (ko) | 2007-12-10 | 2010-09-28 | 알리바 바이오파마수티컬스, 아이엔씨. | 동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법 |
EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
WO2009129247A2 (en) | 2008-04-14 | 2009-10-22 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
US20110123527A1 (en) | 2008-05-23 | 2011-05-26 | Hiroaki Shizuya | Method of generating single vl domain antibodies in transgenic animals |
KR102362774B1 (ko) | 2008-09-30 | 2022-02-15 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 인간 이외의 포유동물 |
MX2011007660A (es) | 2008-12-18 | 2011-08-17 | Kingdon Craig R | Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos. |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
CN103833855A (zh) * | 2009-06-26 | 2014-06-04 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
DK3622813T3 (da) * | 2009-07-08 | 2021-05-03 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
DK2954779T3 (da) | 2009-12-10 | 2019-05-13 | Regeneron Pharma | Mus, der frembringer tungkædeantistoffer |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
CN105695415A (zh) | 2010-06-17 | 2016-06-22 | 科马布有限公司 | 动物模型及治疗分子 |
NZ707327A (en) | 2010-08-02 | 2017-01-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
WO2012063048A1 (en) | 2010-11-08 | 2012-05-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
DE12192727T1 (de) | 2011-02-25 | 2013-07-11 | Regeneron Pharmaceuticals, Inc. | ADAM6 Mäuse |
PT3572517T (pt) | 2011-08-05 | 2021-06-23 | Regeneron Pharma | Murganhos da cadeia leve universal humanizada |
ES2612935T3 (es) | 2011-09-19 | 2017-05-19 | Kymab Limited | Anticuerpos, dominios variables y cadenas adaptados para su uso en seres humanos |
WO2013041845A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Animals, repertoires & methods |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
PL2627773T3 (pl) | 2011-10-17 | 2017-11-30 | Regeneron Pharmaceuticals, Inc. | Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy |
GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
SI2793567T1 (sl) * | 2011-12-20 | 2019-05-31 | Regeneron Pharmaceuticals, Inc. | Humanizirane lahkoverižne miši |
RS57414B1 (sr) | 2012-03-16 | 2018-09-28 | Regeneron Pharma | Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
WO2013144567A1 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
ME03551B (me) | 2012-06-12 | 2020-07-20 | Regeneron Pharma | Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca |
WO2014130690A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
PL3501272T3 (pl) | 2013-03-13 | 2023-07-03 | Regeneron Pharmaceuticals, Inc. | Mysz eksprymująca ograniczony repertuar lekkiego łańcucha immunoglobuliny |
-
2012
- 2012-10-17 PL PL12783456T patent/PL2627773T3/pl unknown
- 2012-10-17 CA CA2850534A patent/CA2850534A1/en active Pending
- 2012-10-17 CN CN201280062449.XA patent/CN104024418B/zh active Active
- 2012-10-17 KR KR1020167021090A patent/KR20160098514A/ko active Search and Examination
- 2012-10-17 EP EP21208060.0A patent/EP4074833A1/en active Pending
- 2012-10-17 PT PT127834562T patent/PT2627773T/pt unknown
- 2012-10-17 AU AU2012326283A patent/AU2012326283C1/en active Active
- 2012-10-17 KR KR1020207012383A patent/KR20200047786A/ko not_active IP Right Cessation
- 2012-10-17 WO PCT/US2012/060487 patent/WO2013059230A1/en active Application Filing
- 2012-10-17 HU HUE17163115A patent/HUE057680T2/hu unknown
- 2012-10-17 SG SG10202010120XA patent/SG10202010120XA/en unknown
- 2012-10-17 LT LTEP12783456.2T patent/LT2627773T/lt unknown
- 2012-10-17 SG SG10201602904VA patent/SG10201602904VA/en unknown
- 2012-10-17 SG SG11201401181YA patent/SG11201401181YA/en unknown
- 2012-10-17 BR BR112014008775A patent/BR112014008775A8/pt not_active Application Discontinuation
- 2012-10-17 RS RS20170893A patent/RS56458B1/sr unknown
- 2012-10-17 DK DK17163115.3T patent/DK3216871T3/da active
- 2012-10-17 ES ES17163115T patent/ES2906462T3/es active Active
- 2012-10-17 KR KR1020197021940A patent/KR102148683B1/ko active IP Right Grant
- 2012-10-17 ES ES12783456.2T patent/ES2640139T3/es active Active
- 2012-10-17 KR KR1020217028212A patent/KR20210113419A/ko not_active IP Right Cessation
- 2012-10-17 MY MYPI2014000810A patent/MY172946A/en unknown
- 2012-10-17 PL PL17163115T patent/PL3216871T3/pl unknown
- 2012-10-17 KR KR1020147013282A patent/KR20140082824A/ko active Search and Examination
- 2012-10-17 HU HUE12783456A patent/HUE034321T2/en unknown
- 2012-10-17 IN IN3572CHN2014 patent/IN2014CN03572A/en unknown
- 2012-10-17 LT LTEP17163115.3T patent/LT3216871T/lt unknown
- 2012-10-17 IL IL292030A patent/IL292030B2/en unknown
- 2012-10-17 JP JP2014535991A patent/JP6271435B2/ja active Active
- 2012-10-17 US US13/653,456 patent/US10246509B2/en active Active
- 2012-10-17 MX MX2014004354A patent/MX355062B/es active IP Right Grant
- 2012-10-17 RU RU2016139418A patent/RU2743589C2/ru active
- 2012-10-17 HR HRP20220253TT patent/HRP20220253T1/hr unknown
- 2012-10-17 RS RS20220181A patent/RS62942B1/sr unknown
- 2012-10-17 DK DK12783456.2T patent/DK2627773T3/en active
- 2012-10-17 SI SI201231055T patent/SI2627773T1/sl unknown
- 2012-10-17 RU RU2014118869/10A patent/RU2603090C2/ru active
- 2012-10-17 SI SI201231981T patent/SI3216871T1/sl unknown
- 2012-10-17 PT PT171631153T patent/PT3216871T/pt unknown
- 2012-10-17 EP EP17163115.3A patent/EP3216871B1/en active Active
- 2012-10-17 KR KR1020237045077A patent/KR20240006704A/ko not_active Application Discontinuation
- 2012-10-17 CN CN201710933685.9A patent/CN108200885B/zh active Active
- 2012-10-17 EP EP12783456.2A patent/EP2627773B1/en active Active
- 2012-10-17 CN CN201710933842.6A patent/CN108207807B/zh active Active
-
2013
- 2013-07-17 US US13/944,286 patent/US9932398B2/en active Active
-
2014
- 2014-03-31 IL IL231819A patent/IL231819A0/en active IP Right Grant
- 2014-04-01 ZA ZA2014/02455A patent/ZA201402455B/en unknown
-
2015
- 2015-11-12 JP JP2015222017A patent/JP2016039820A/ja active Pending
-
2016
- 2016-06-17 AU AU2016204127A patent/AU2016204127C1/en active Active
-
2017
- 2017-09-11 HR HRP20171357TT patent/HRP20171357T1/hr unknown
- 2017-09-12 CY CY20171100960T patent/CY1119335T1/el unknown
- 2017-09-27 JP JP2017186356A patent/JP2017221223A/ja active Pending
-
2018
- 2018-05-30 AU AU2018203811A patent/AU2018203811B2/en active Active
- 2018-08-20 IL IL261242A patent/IL261242A/en active IP Right Grant
- 2018-12-27 JP JP2018244321A patent/JP6770568B2/ja active Active
-
2019
- 2019-02-01 US US16/265,825 patent/US11261248B2/en active Active
- 2019-04-11 IL IL265967A patent/IL265967B/en active IP Right Grant
-
2020
- 2020-04-17 US US16/851,902 patent/US20200277371A1/en not_active Abandoned
- 2020-09-25 JP JP2020161346A patent/JP7022803B2/ja active Active
- 2020-12-18 AU AU2020289846A patent/AU2020289846A1/en not_active Abandoned
-
2021
- 2021-04-08 IL IL282200A patent/IL282200B/en unknown
- 2021-12-29 JP JP2021215393A patent/JP2022048158A/ja not_active Withdrawn
-
2022
- 2022-01-19 US US17/579,185 patent/US20220177572A1/en active Pending
- 2022-02-07 CY CY20221100102T patent/CY1124972T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014008775A2 (pt) | camundongo de cadeia pesada de imunoglobulina restrita | |
BR112013020500A2 (pt) | anticorpo isolado, recombinante ou purificado | |
BR112012019887A2 (pt) | camundongo da cadeia leve comum | |
BR112015011518B8 (pt) | Anticorpo heterodimérico, ácido nucleico e vetor | |
BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
MX353278B (es) | Raton con cadena ligera comun. | |
NZ781020A (en) | Humanized universal light chain mice | |
UY30776A1 (es) | Anticuerpos cd44 | |
BR112015027812A2 (pt) | processo contínuo de multietapa para purificação de anticorpos | |
MX341921B (es) | Proteinas de union a antigeno. | |
EA201491569A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
UA116766C2 (uk) | Зв'язувальна молекула, яка є біоспецифічною до вcma і cd3 | |
BR112014006390A2 (pt) | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano | |
BR112014009066B8 (pt) | molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica | |
CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
CL2013001089A1 (es) | Anticuerpos que se une especificamente a tnfalfa humano; composicion farmacéutica que la comprende; molécula de ácido nucleico aislado; vector; metodo para reducir la tendencia a la agregación de un anticuerpo. | |
EP4218409A3 (en) | Mice expressing a limited immunoglobulin light chain repertoire | |
MX2015012540A (es) | Ratón de cadena ligera común. | |
CL2014000574A1 (es) | Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. | |
MX2017004117A (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |